Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Replimune, Inc.
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06581406CT.gov A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| rp2 (this asset) | Replimune, Inc. | P2/3 | CCC · 54 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for rp2
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 53 |
| Marinesco-Sjogren Syndrome | — | P2 | CCC · 53 |
| Biliary Tract Cancer | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. rp2 in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rp2-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →